|
Bromodomain-2 Selective BET inhibitors
|
6
|
Resverlogix Corp.
|
Apr 19, 2018 10:35AM
|
|
Bromodomain-containi... proteins in prostate cancer
|
2
|
Zenith Epigenetics
|
Feb 05, 2019 10:37AM
|
|
Bromodomains: a new target class for drug development
|
6
|
Resverlogix Corp.
|
Jul 16, 2019 07:18AM
|
|
BTI
|
2
|
Resverlogix Corp.
|
Nov 23, 2015 11:25AM
|
|
CANTOS and CIRT
|
5
|
Resverlogix Corp.
|
Nov 10, 2017 04:30PM
|
|
CANTOS good, but FDA not on board with sub-group analysis
|
6
|
Resverlogix Corp.
|
Oct 18, 2018 02:03PM
|
|
Cardiovascular organ damage in T2DM: the role of lipids and inflammation
|
5
|
Resverlogix Corp.
|
May 11, 2019 08:20AM
|
|
Clarification on BETonMACE baseline data
|
10
|
Resverlogix Corp.
|
Sep 04, 2019 12:43PM
|
|
Clinical Steering Committee meeting for BETonMACE?
|
5
|
Resverlogix Corp.
|
Aug 24, 2018 09:54AM
|
|
Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
|
5
|
Resverlogix Corp.
|
Jul 19, 2018 02:44PM
|
|
Colchicine....strong support of inflammation hypothesis
|
6
|
Resverlogix Corp.
|
Aug 31, 2020 12:28PM
|
|
COLCORONA trial: Colchicine reduces the risk of COVID-19-related complications
|
4
|
Resverlogix Corp.
|
Jan 23, 2021 11:06AM
|
|
Collection of ERA-EDTA and ESC Resverlogix Sponsored Symposia Videos
|
10
|
Resverlogix Corp.
|
Aug 15, 2019 02:38PM
|
|
Compilation of BET inhibitor Trials
|
7
|
Resverlogix Corp.
|
Oct 05, 2017 01:13PM
|
|
Compilation of BET inhibitor Trials
|
5
|
Zenith Epigenetics
|
Oct 05, 2017 01:21PM
|
|
Compliment in Human Disease meeting at end of this month
|
3
|
Resverlogix Corp.
|
Jun 18, 2015 03:51PM
|
|
Compounds and Autoimmune
|
8
|
Zenith Epigenetics
|
Jun 21, 2016 12:10PM
|
|
Compounds and Autoimmune
|
5
|
Resverlogix Corp.
|
Jun 21, 2016 12:12PM
|
|
Constellation Pharma news, courtesy of rndtbl
|
5
|
Zenith Epigenetics
|
Nov 06, 2019 04:06PM
|
|
Constellation Pharmaceuticals Readies $80 Million IPO Plans
|
7
|
Zenith Epigenetics
|
Jul 20, 2018 10:14AM
|
